#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Asthma Dermatitis atopic Dementia Alzheimer's type Type 2 diabetes mellitus Breast cancer metastatic Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Crigler-Najjar syndrome Ovarian cancer stage IV Nasopharyngeal cancer Angelman's syndrome Cushing's syndrome Neuropathic arthropathy Metachromatic leukodystrophy Metastases to central nervous system Chronic inflammatory demyelinating polyradiculoneuropathy Retinitis pigmentosa Neuroendocrine carcinoma Hypochromic anaemia Pyoderma gangrenosum Progressive supranuclear palsy Chorioretinitis More trials…

    Learn about Rare Diseases

    Synovial sarcoma – Treatment Congenital generalised lipodystrophy – Trials in Disease Fabry’s disease – Basic Information Waldenstrom’s macroglobulinaemia – Life with Disease Hereditary angioedema with C1 esterase inhibitor deficiency – Basic Information Retinoblastoma – Life with Disease Angiosarcoma – Trials in Disease Osteosarcoma – Life with Disease Noonan syndrome Medulloblastoma recurrent – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    INCB123667 Caplacizumab Tasipimidine Timolol Bdc-1001 Sodium Hydrogen Carbonate Sodium Citrate Alx148 Adct-402 Balcinrenone Azd5004 Annamycin HRS 9531 Glutathione Reboxetine Satralizumab Pembrolizumab Ponesimod Sacubitril Collagenase More therapies…

    Learn about Your Condition

    Corneal graft failure Duchenne muscular dystrophy Myocarditis post infection Spinal cord injury cervical Pancreatic neoplasm Gender dysphoria Aicardi-Goutieres syndrome Vertigo Pelizaeus-Merzbacher disease Psoriatic arthropathy Breast cancer stage II Bartonellosis Chondrocalcinosis Vascular graft thrombosis Malignant peritoneal neoplasm More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Hestia Duran I Reynals

Hestia Duran I Reynals

Avinguda de la Granvia de l'hospitalet 199-203, L'hospitalet De Llobregat, 08908, Spain

Want to learn more about this study or check if you can participate? Contact us.

  • Study on the Effectiveness of Optune with Temozolomide and Pembrolizumab in Patients with Newly Diagnosed Glioblastoma

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Glioblastoma
    Investigated Drugs:
    • Temozolomide
    • Pembrolizumab
    Czechia France Germany Italy Poland Spain

  • Study on Enfortumab Vedotin for Patients with Advanced Neuroendocrine Carcinoma Not Responding to or Ineligible for Platinum Chemotherapy

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Neuroendocrine carcinoma
    Investigated Drugs:
    • Enfortumab Vedotin
    Spain

  • Study of AloCelyvir for Patients with Metastatic Uveal Melanoma

    Not recruiting

    1 1 1
    Investigated Diseases:
    • Uveal melanoma
    Investigated Drugs:
    • Allogenic Bone Marrow-Derived Mesenchymal Stem Cells Transduced With Icovir-5, Ex Vivo Expanded
    Spain

  • Study of SBP-101, Nab-Paclitaxel, and Gemcitabine for Patients with Metastatic Pancreatic Cancer

    Not recruiting

    4 1 1
    Investigated Diseases:
    • Ductal adenocarcinoma of pancreas
    Investigated Drugs:
    • Ivospemin
    • Sodium Hydrogen Carbonate Pheur
    • Gemcitabine
    Austria Belgium France Germany Italy Spain

  • Study on Iberdomide and Dexamethasone, Alone or with Drug Combination, for Newly Diagnosed Multiple Myeloma Patients Not Eligible for Transplant

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    • Iberdomide
    • Daratumumab
    Spain

  • Study on CTL-002 and Nivolumab for Patients with Advanced-Stage, Relapsed/Refractory Solid Tumors

    Not recruiting

    1 1 1 1
    Investigated Diseases:
    • Neoplasm
    Investigated Drugs:
    • VISUGROMAB
    • Cemiplimab
    • Nivolumab
    Germany Spain

  • Study on the Effectiveness and Safety of Tiragolumab, Atezolizumab, and Drug Combination for Patients with Urothelial Carcinoma

    Not recruiting

    1 1 1 1
    Investigated Drugs:
    • Tiragolumab
    • Atezolizumab
    • Cisplatin
    France Greece Spain

  • Study Comparing Lenalidomide, Bortezomib, Dexamethasone, Isatuximab, and Iberdomide for Newly Diagnosed Multiple Myeloma Patients Eligible for Stem Cell Transplant

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    Investigated Drugs:
    • Iberdomide
    • Isatuximab
    • Bortezomib
    Spain

  • Study on Birtamimab and Bortezomib for Patients with Advanced Light Chain Amyloidosis

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Primary amyloidosis
    Investigated Drugs:
    • Birtamimab
    • Bortezomib
    • Sodium Chloride
    Austria Belgium Czechia Denmark France Germany +8
Previous Page
1 2

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!